Informa

AsiaTIDES: Oligonucleotide & Peptide Therapeutics
-AsiaTIDES:寡核苷酸及胜肽疗法-
日期:2019年2月26-28日
地点:日本,千叶县,Hilton Tokyo Bay Hotel

本活动是亚洲地区唯一介绍有助于加速寡核苷酸及胜肽疗法上市作业的研究成果与技术,并提供合作机会的活动

Choose your language
Chinese
Japanese
Korean
English

AsiaTIDES 2019的主要讲者与讲题

寡核苷酸

寡核苷酸疗法开发的新策略与技术
Thazha Prakash, Ph.D., Director, Medicinal Chemistry, Ionis Pharmaceuticals, USA

处于第一期/前期、第二期临床试验的治疗湿眼式老年黄斑部病变(wet AMD)的抗FGF2适体 ― RBM-007
Yoshikazu Nakamura, Ph.D., President and CEO, RIBOMIC Inc., and Professor Emeritus, The University of Tokyo, Japan

新RNA疗法:可用于mRNA及siRNA的运送方法
Shiro Akinaga, Ph.D., Director, Chief Scientific Officer, AccuRna Inc., Japan

题目将于日后公布
Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals

从立体化学纯度到精密医疗:最佳化反股核酸疗法的特性
WAVE Lifesciences, Speaker TBA


mRNA疗法

mRNA疗法入门
Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics, USA

新mRNA免疫疗法
Robert Jabulowsky, Ph.D., Deputy Head of Project Management, BioNTech AG, Germany

mRNA疗法开发
Nigel Horscroft, D.Phil., Area Head, Molecular Therapy, CureVac AG, Germany 

mRNA药物运送的最佳化
Peter Lutwyche, Ph.D., Chief Technology Officer, Genevant Sciences Corporation, Canada 

寡核苷酸及胜肽疗法的法规面课题

寡核苷酸及胜肽疗法的法规策略,以及中国国家食品药品监督管理总局(CFDA)法规改革的最新情报
Dan Zhang, M.D., Co-Founder & CEO, Fountain Medical Development, China

胜肽与医疗仪器组合产品开发相关法规课题
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA 

寡核苷酸疗法的法规策略
David T. Lin, Ph.D., Senior Consultant, Biologics Consulting, (Former Chemistry Team Leader and Former Acting Division Director, Division of New Drug Chemistry, CDER, FDA), USA

 

寡核苷酸(续)

次世代锁核酸
Konrad Bleicher, RNA Therapeutics, Roche Pharma Preclinical Research and Early Development, Roche Innovation Centre Basel, F. Hoffmann-La Roche Ltd., Switzerland

题目将于日后公布
Satoshi Inoue, Ph.D., Scientist, Bio-functional Molecular Chemistry Group, Ajinomoto Co., Inc., Japan

胜肽

环状构造及二环状结构的遗传符号化选择
Ratmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada

液态胜肽制造工程用的永续性低公害型溶剂导入
El Djouhar Rekai, Ph.D., Head of Development & Manufacturing Process, PolyPeptide Group, Belgium

胜肽的品质特性与美国FDA标准
Ranjan Chakrabarti, Ph.D., Vice President & Head - Global Biologics Lab and Standards, United States Pharmacopeia, India

ZEOsphere DRP混合模式层析的高性价比胜肽纯化
Jurgen Machielse, Business Development Director, Zeochem AG, Switzerland

胜肽合成的线性收敛方法 ― 制造商观点比较
Daniel Samson, Ph.D., Vice President API SPPS, Bachem AG, Switzerland

胜肽(续)

合成胜肽原药的课题
Robert Hagopian, Director Business Development, PolyPeptide Group

对应早期开发阶段的分析法、预备处方、处方
Christopher Rhodes, Ph.D., President and CEO, Drug Delivery Experts 

毒性学与生物学分析的策略/第一阶段临床试验的策略
Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest

美国胜肽药与胜肽生物制剂间,产品开发的相似及相异之处
Duu-Gong Wu, Ph.D., Senior Director, Regulatory Consulting, PPD (and Former Deputy Division Director of Division of New Drug Chemistry, CDER, FDA), USA

请勿错过这个能够在ASIATIDES找寻业务发展时不可或缺之研究成果、技术、合作夥伴的机会

加速产品上市

除了可以聆听全球正在进行第2及第3期临床试验的寡核苷酸、肽治疗药开发企业的案例研讨和最佳范例相关演讲,并将由产业领袖分享从申请到核准成功推动IND/IMPD的指南和Roadmap,以确保产品通过审核。

评估新技术和服务

透过与20多间全球领导技术开发企业的会晤,改善您的制程开发、分析、制造作业。此外也在展示会大厅安排了海报发表,将展示全球研究人员针对寡核苷酸及肽开发各阶段的最新研究成果。

与新合作夥伴会面

透过午餐、晚餐、招待会等机会,能够与300多位来自亚洲、欧洲、北美等地的寡核苷酸及肽研究领导者建立人脉。

CROSS-FERTILIZE IDEAS AND BEST PRACTICES WITH RESEARCHERS FROM DIFFERENT DISCIPLINES

Oligonucleotide Track Highlights
  • Learn about advances in mRNA therapeutic development and CMC
  • Find new approaches to optimize oligonucleotide properties
  • Increase efficiency in oligonucleotide CMC and manufacturing
  • Overcome the delivery challenge by learning about new delivery technologies
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Oligonucleotides to IND and Beyond
Peptide Track Highlights
  • Implement new approaches for peptide discovery and drug target identification
  • Discover the latest in peptide synthesis technologies and methods
  • Find new approaches to optimize peptide properties
  • Increase efficiency in peptide CMC and manufacturing
  • Hear data from preclinical and clinical case studies with lessons learned
  • Pre-Conference Workshop: Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond
NEW this year for 2019
  • mRNA therapeutics session featuring Moderna Therapeutics, BioNTech and CureVac
  • 1st Time Presenting Companies: WAVE, Stoke, CuroNZ, NapaJen, FunPep and more!
  • Expanded regulatory session for both peptides and oligonucleotides
  • More exhibitors and poster presentations than ever before

Present a Scientific Poster

Share your company's new research by presenting a poster in the exhibit & poster hall at AsiaTIDES

Please note that all poster presenters must be registered attendees. Poster submission deadline is January 29.

AsiaTIDES 2019谘询委员会

  • Hiroaki Suga, Ph.D., Professor of Chemistry, School of Science, University of Tokyo, Japan 
  • Osamu Sato, Executive Director, R&D Planning Department, Daiichi Sankyo, Japan 
  • Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals 
  • James Thompson, Ph.D., Head of CMC Project Management, Moderna Therapeutics, Inc. 
  • Hideaki Sato, President and CEO Luxna Biotech
  • Robert Hagopian, Director Business Development, PolyPeptide Laboratories, USA
  • Daisuke Takahashi, Ph.D., Senior Principal Researcher, Bio-functional Molecular Chemistry Group, Research Institute for Bioscience Products & Fine Chemicals, Ajinomoto. Co., Inc., Japan
  • Dong-ki Lee, Ph.D., Professor, Sungkyunkwan University and CEO & Founder, OliX Pharmaceuticals, Korea 
  • Shawn Lee, Ph.D., President and CEO, CPC Scientific, USA and China 
  • Patrick Lu, Ph.D., Founder, President and CEO, Sirnaomics, Inc., USA 
  • Michael McGinley, Global Technical Manager, Phenomenex, USA
  • Bruce Morimoto, Ph.D., Vice President, Drug Development-Operations, Alkahest 
  • El Djouhar Rekai, Head of Peptide Products Operation, PolyPeptide Group, Belgium G. 
  • Susan Srivatsa, Ph.D., President, ElixinPharma, USA 
  • Dmitry Samarsky, Ph.D., Industry Expert 
  • Mimoun Ayoub, Ph.D., Director and Head of North American and Emerging Markets, CordenPharma International, Switzerland

PARTNERING OPPORTUNITIES FOR ASIATIDES 2019


Meet the People Behind the Products and Get the Answers You Need

Highlight your company's expertise to 300+ Oligo and Peptide Decision Makers working across peptide & oligonucleotide development.